The data presented here supports an important and vital role for LAMTOR4 as a biomarker associated with prostate cancer progression and metastasis and with significant clinical outcome prognostic value as an individual biomarker or in association with PTEN loss/ERG expression. Here, PTEN is linked to prostate cancer.